WO2024042554A1 - Composition pharmaceutique pour le traitement d'infections virales - Google Patents

Composition pharmaceutique pour le traitement d'infections virales Download PDF

Info

Publication number
WO2024042554A1
WO2024042554A1 PCT/IN2023/050806 IN2023050806W WO2024042554A1 WO 2024042554 A1 WO2024042554 A1 WO 2024042554A1 IN 2023050806 W IN2023050806 W IN 2023050806W WO 2024042554 A1 WO2024042554 A1 WO 2024042554A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
composition
compound
analogue
precursors
Prior art date
Application number
PCT/IN2023/050806
Other languages
English (en)
Inventor
Amitabha Majumdar
Naresh Ghatlia
Colin Jamora
Tanay Nitinkumar BHATT
Original Assignee
Istituto Fondazione Di Oncologia Molecolare Ets
Institute For Stem Cell Science And Regenerative Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Fondazione Di Oncologia Molecolare Ets, Institute For Stem Cell Science And Regenerative Medicine filed Critical Istituto Fondazione Di Oncologia Molecolare Ets
Publication of WO2024042554A1 publication Critical patent/WO2024042554A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La présente invention concerne une composition pharmaceutique comprenant : (i) un acide gras activant le récepteur activé de la prolifération des peroxysomes (PPAR) et/ou un composé de cathélicidine (LL37), ses précurseurs ou ses analogues ; (ii) un composé de vitamine B3, son précurseur ou son analogue ; et (iii) des additifs et des supports pharmaceutiquement acceptables. La composition de l'invention est utile dans le traitement d'une infection virale. De préférence, la composition est utile pour traiter une infection virale causée par un coronavirus ou un virus de la grippe ou de la dengue.
PCT/IN2023/050806 2022-08-25 2023-08-25 Composition pharmaceutique pour le traitement d'infections virales WO2024042554A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202211048425 2022-08-25
IN202211048425 2022-08-25

Publications (1)

Publication Number Publication Date
WO2024042554A1 true WO2024042554A1 (fr) 2024-02-29

Family

ID=88316024

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2023/050806 WO2024042554A1 (fr) 2022-08-25 2023-08-25 Composition pharmaceutique pour le traitement d'infections virales

Country Status (1)

Country Link
WO (1) WO2024042554A1 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010028067A1 (fr) * 2008-09-02 2010-03-11 Amarin Corporation Plc Composition pharmaceutique comprenant de l'acide eïcosapentaénoïque et de l'acide nicotinique et ses procédés d'utilisation
WO2015051260A2 (fr) * 2013-10-03 2015-04-09 Crawford Keith D Composition pour les soins de la peau contenant une substance biologique
WO2015061512A1 (fr) * 2013-10-24 2015-04-30 The Procter & Gamble Company Compositions cosmétiques éclaircissant la peau et méthodes correspondantes
WO2015172801A1 (fr) * 2014-05-12 2015-11-19 Unilever N.V. Niacinamide induisant la production de peptides antimicrobiens
US10105332B1 (en) * 2017-10-19 2018-10-23 David G. Changaris Methods and composition for suppression of deep seated fungal growth on skin
WO2021209993A1 (fr) * 2020-04-13 2021-10-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Utilisation de régulateurs métaboliques pour le traitement de la covid-19
WO2022117404A1 (fr) * 2020-12-03 2022-06-09 Unilever Ip Holdings B.V. Acide hydroxystéarique pour induire la génération de peptides antimicrobiens
WO2023094517A1 (fr) * 2021-11-26 2023-06-01 Unilever Ip Holdings B.V. Composition topique

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010028067A1 (fr) * 2008-09-02 2010-03-11 Amarin Corporation Plc Composition pharmaceutique comprenant de l'acide eïcosapentaénoïque et de l'acide nicotinique et ses procédés d'utilisation
WO2015051260A2 (fr) * 2013-10-03 2015-04-09 Crawford Keith D Composition pour les soins de la peau contenant une substance biologique
WO2015061512A1 (fr) * 2013-10-24 2015-04-30 The Procter & Gamble Company Compositions cosmétiques éclaircissant la peau et méthodes correspondantes
WO2015172801A1 (fr) * 2014-05-12 2015-11-19 Unilever N.V. Niacinamide induisant la production de peptides antimicrobiens
US10105332B1 (en) * 2017-10-19 2018-10-23 David G. Changaris Methods and composition for suppression of deep seated fungal growth on skin
WO2021209993A1 (fr) * 2020-04-13 2021-10-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Utilisation de régulateurs métaboliques pour le traitement de la covid-19
WO2022117404A1 (fr) * 2020-12-03 2022-06-09 Unilever Ip Holdings B.V. Acide hydroxystéarique pour induire la génération de peptides antimicrobiens
WO2023094517A1 (fr) * 2021-11-26 2023-06-01 Unilever Ip Holdings B.V. Composition topique

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"Remington: The Science and Practice of Pharmacy", 2000, LIPPINCOTT WILLIAMS & WILKINS
BELVISI, M.GMITCHELL, J.A: "Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease", BRITISH JOURNAL OF PHARMACOLOGY, vol. 158, 2009, pages 994 - 1003, XP071123676, DOI: 10.1111/j.1476-5381.2009.00373.x
BRAFF, MGALLO, R: "Antimicrobial peptides: an essential component of the skin defensive barrier", ANTIMICROBIAL PEPTIDES AND HUMAN DISEASE, 2006, pages 91 - 110
CONNORS, T.JRAVINDRANATH, T.MBICKHAM, K.LGORDON, C.LZHANG, FLEVIN, BBAIRD, J.SFARBER, D.L: "Airway CD8+ T cells are associated with lung injury during infant viral respiratory tract infection", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, vol. 54, 2016, pages 822 - 830
DURR, U.HSUDHEENDRA, URAMAMOORTHY, A: "LL-37, the only human member of the cathelicidin family of antimicrobial peptides", BIOCHIMICA ET BIOPHYSICA ACTA (BBA)-BIOMEMBRANES, vol. 1758, 2006, pages 1408 - 1425
KURPE STANISLAV R. ET AL: "Antimicrobial and Amyloidogenic Activity of Peptides. Can Antimicrobial Peptides Be Used against SARS-CoV-2?", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 21, no. 24, 15 December 2020 (2020-12-15), pages 1 - 37, XP055865358, DOI: 10.3390/ijms21249552 *
MERNFIELD, R: "Solid phase peptide synthesis. II. The synthesis of bradykinin", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 86, 1964, pages 304 - 305
ZELEZETSKY, IPONTILLO, APUZZI, LANTCHEVA, NSEGAT, LPACOR, SCROVELLA, STOSSI, A: "Evolution of the Primate Cathelicidin: <em>CORRELATION BETWEEN STRUCTURAL VARIATIONS AND ANTIMICROBIAL ACTIVITY</em>*<sup></sup", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, 2006, pages 19861 - 19871

Similar Documents

Publication Publication Date Title
US8852582B2 (en) Compositions comprising glutathione reductase and oxidized glutathione
AP1356A (en) Antimicrobial treatment for herpes simplex virus and other infectious diseases.
US10130648B2 (en) Therapeutic composition
AU2011212256A1 (en) Treatment of respiratory disorders
JP2010517987A (ja) 塩基性ペプチド及びその複合型抗細菌−抗真菌剤としての使用
JP2015108009A (ja) 癌細胞においてアポトーシスを誘導する方法および使用
US20200054595A1 (en) EGCG-Palmitate Compositions and Methods of Use Thereof
CN113164420A (zh) 治疗组合物
Burgess et al. A phospholipid–apolipoprotein AI nanoparticle containing amphotericin B as a drug delivery platform with cell membrane protective properties
EA017705B1 (ru) Способ подавления ортопоксвирусных инфекций
JP2013533308A (ja) ニコチン酸アデニンディヌクレオチドリン酸又はその誘導体を含む薬学又は化粧料組成物
WO2024042554A1 (fr) Composition pharmaceutique pour le traitement d&#39;infections virales
US20190008930A1 (en) Mycobacterium lysterase: a novel treatment for acne
CA2123780A1 (fr) Composition a base d&#39;amphotericine b ayant une activite antifongique amelioree
US9446017B2 (en) Compositions and methods for treating herpes simplex virus
EP0739629B1 (fr) Nouvelles associations comprenant du (-)hydroxycitrate et présentant notamment de nouvelles activités thérapeutiques
EP2559432B1 (fr) Moyen pour la prévention et le traitement de pancréatite aiguë et chronique
BR102012006217A2 (pt) Composição compreendendo polifenol de chá verde para uso no tratamento de infecção pelo vírus herpes simples (hsv)
US6043268A (en) Agent for treatment of viral infections
WO2009007827A2 (fr) Nouveaux esters de diclofénac et utilisations de ceux-ci
FR2887249A1 (fr) Compose d-glucopyranose 1-[3,5-bis(1,1-dimenthylethyl)-4- hydroxybenzoate] et ses derives, leur preparation et leurs utilisations
US20100016244A1 (en) D-glucopyranose 1-[3,5-bis (1,1-dimethylethy)-4-hydroxybenzoate] and its derivatives, preparation and use thereof
EP3735257A2 (fr) Extraits végétaux pour le traitement d&#39;infections par le virus de l&#39;herpès
US20200069585A1 (en) Compositions for upregulating defensin expression
JP4879332B2 (ja) 神経障害性疼痛抑制薬

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23786785

Country of ref document: EP

Kind code of ref document: A1